HRI Portal – health • research • innovation

  • About Us
    • About Research Canada
    • Sponsors
    • Contact
  • Information on Health Research
    and Innovation in Canada
    • The Current State of Health Research
      and Innovation in Canada
    • Research and Innovation in Action
    • CanadaSpeaks! 2019
    • Patient Stories
    • What’s Being Said:
      Blog and News
  • Resources for
    Advocates
    • Advocacy Messages
    • Tips for Effective Advocacy
      • Quick Tips for Effective Advocacy
      • Meeting with Candidates: Policy Questions and Answers
      • Using Social Media for Advocacy
      • Maximizing Your Impact: Town Halls
    • About Your Candidates
    • Advocates’ Toolkit
  • Resources for
    Candidates
    • Information on Health Research and Innovation
    • Candidate Survey

Research and Innovation in Action

  1. Home
  2. › Information on Health Research and Innovation in Canada
  3. › Research and Innovation in Action
  4. › Alberta sisters participate in clinical trial to advance treatment options for rare genetic disorder

Alberta sisters participate in clinical trial to advance treatment options for rare genetic disorder

University of Calgary


At a consultation with their neurologist, two members of an Alberta family affected by the genetic disorder facioscapulohumeral muscular systrophy (FSHD) learned about a clinical trial that tests a new leading edge treatment. Recognizing the importance of research to advance treatment, the two sisters, who have asked not to have their last name used, decided to participate in the clinical trial program.

“I was so excited, I jumped all over it,” says Lynn. “FSHD affects everything from daily activities, to work choices, marriage, planning a family, it is a huge part of who you are.”

FSHD is an inherited neuromuscular disorder that causes weakness of the muscles, most often, in the face, shoulder blades, and upper arms. It can progress to cause widespread muscle weakness, as well as loss of hearing. Currently, there is no standard of care treatment for this disease.

“I feel it is my responsibility to contribute as a patient to make progress possible,” says Heather.

Dr. Lawrence Korngut, MD, an associate professor in the departments of Clinical Neurosciences and Community Health Sciences and member of the Hotchkiss Brain Institute at the Cumming School of Medicine (CSM), is a global leader in researching new treatments for neuromuscular conditions. He and his team, clinical trial co-ordinators Janet Petrillo and Jose Martinez, were recognized as having the highest recruitment of participants worldwide to the FSHD clinical trial program, which was conducted at close to 20 sites in North America and Europe.

 

Bringing clinical trial opportunities to Calgary

“As a physician and researcher, I was very happy to be able to offer a cutting-edge treatment option to my patients,” says Korngut, who is also director of the Calgary ALS and Motor Neuron Disease Clinic. “We need advances in these rare diseases and our team is dedicated to bringing clinical trial opportunities to our Calgary patients.”

Both sisters appreciated the care they received throughout their clinical trial participation. “I was very impressed with how supportive the entire team was,” says Heather. “The appointments can take a lot of time, and the team worked hard to make it as easy as possible for me to participate; often, booking appointments around my work schedule.”

“It was a positive experience. The staff are wonderful people. Jose was incredible, he made me feel comfortable at all times,” says Lynn. “A big thank you to Dr. Korngut for making this possible.”

Due to the success of the trials Heather and Lynn participated in, an extension phase has now been offered that will allow them continued opportunities to participate in the studies.

Clinical trials underway are looking for participants

For those considering participation in a clinical trial, Heather has the following advice: “Talk to the team, if you have concerns or reservations, they are more than happy to inform you and answer your questions. There was no pressure, and I never felt that anyone would be disappointed if I had decided not to participate.”

 

This article was originally published on May 15, 2019 by Sabine Moritz, University of Calgary.

New skin cancer probe could expand access to a prompt diagnosisPreschoolers’ physical activity can have impact on heart health later in life

Contact Us

Tweets

  • 1 hour ago The 2nd panel at our virtual #HealthResearchCaucus reception will use their expertise to answer your cancer diagnos… https://t.co/9uIWrxKnLj
  • 21 hours ago It's #LabWeek! National Medical Laboratory Week is the perfect time to recognize Canada's medical laboratory profes… https://t.co/D3kQBx8nmn
  • 22 hours ago On April 29, we’ll be joined by 6 experts working on #CancerResearch and innovation in Canada for the 1st panel of… https://t.co/s8cVRg4ULP
  • 1 day ago RT @usask: “The overall goal of this project is to increase the sharing of COVID-19 information among nurses across Canada.” #USask researc…

About Research Canada

Research Canada is a national, broad-based alliance dedicated to increasing investments in health research through collaborative advocacy. We believe health research is shared benefit, shared responsibility and an investment in Canada’s future. We engage government, academia, industry and non-profit sectors to build support for balanced and long-term health research funding – investments that strengthen Canada’s innovation system and lead to better health, sustainable health care, new commercialization opportunities, and skilled jobs for Canadians.

Research Canada: An Alliance for Health Discovery / Recherche Canada : Une alliance pour les découvertes en santé
Your Candidates, Your Health Your Candidates, Your Health
HRI Portal – health • research • innovation
  • Sponsors
  • Health Research
    and Innovation
  • Resources for
    Candidates
  • Resources for
    Advocates
  • What’s Being Said:
    Blog and News
  • Contact
Research Canada/Recherche Canada © 2019 | All Rights Reserved | Tous droits réservés.